We also demonstrate that high BIM protein expression positively correlated with increased sensitivity to the PI3K/mTOR and BCL-2/BCL-XL inhibitor combination, consistent with an ex vivo tumor slice study of single-agent ABT-737 treatment56. The gene discussed is BCL2L1; the disease is neoplasm.